Article record

社区药房促进癌症早期检测的干预措施：一项系统综述

Interventions to promote the early detection of cancer in community pharmacies: a systematic review.

综述 Meta鼻科IF 2.3Q3

文献信息

PMID	42760275
原文	在 PubMed 查看原文 ↗
发表日期	2026
作者	Shereen Nabhani Gebara 查看其他 5 位作者 Natalie McFadyen Weir；Lisa Macleod；Helen Winter；Ade Williams；Margaret Watson
作者单位	Professor of Oncology at Kingston University London, Department of Pharmacy, Kingston Upon Thames, KT12EE and Chair of British Oncology Pharmacy Association (BOPA), United Kingdom. 查看其他 5 条单位信息 Lecturer/Community Pharmacist Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow G1 1XQ, United Kingdom.；Research Pharmacist, University of Stirling, Stirling FK9 4NH, United Kingdom.；Consultant Medical Consultant, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS1 3NU, United Kingdom.；Superintendent Pharmacist, Bedminster Pharmacy, Bristol BS3 4EJ, United Kingdom.；Professor of Health Service Research and Pharmacy Practice, University of Strathclyde, Glasgow G1 1XQ and Director, Watson and Training Limited, Aberdeen, United Kingdom.
期刊	The International journal of pharmacy practice
SCI 分区	Q3
IF	2.3
研究类型	综述 Meta · 临床
所属专科	鼻科

中文摘要

目的： 癌症的早期发现和诊断与更高的治疗成功率和改善的生存率相关。社区药房通常是出现可能由癌症引起的症状（如持续性咳嗽、直肠出血、吞咽困难）的患者的首个接触点，并可能有助于更早地发现癌症。
方法： 本系统综述评估了基于社区药房的干预措施支持癌症早期检测的证据。检索了五个数据库（Medline、EMBASE、HMIC、CINAHL和PSYCINFO）及其他补充来源，时间范围为2000年1月至2025年2月。采用遵循PRISMA指南的标准系统综述方法。进行了独立双人筛选、研究选择、数据提取和质量评估。
主要发现： 共纳入来自10个国家的27项研究。涉及多种癌症类型，包括结直肠癌（n=13）、肺癌（n=4）、皮肤癌（n=4）、乳腺癌（n=1）、前列腺癌（n=1）、乳腺癌和宫颈癌（n=1）、胃癌（n=1）、结直肠癌和前列腺癌（n=1），以及一项研究包含多种癌症类型。干预措施包括针对性筛查（n=2）、人群筛查（n=15）、分诊（n=8）和健康促进（n=2）。在报告癌症诊断率的10项研究中，共检测出3274例癌性或癌前病变：结直肠癌（n=2816）；前列腺癌（n=14）；皮肤癌（n=453），转诊转化率在3.4%至8.5%之间。
结论： 利用社区药房工作人员的专业知识可能有助于患者更早、更快地诊断癌症。将社区药房纳入早期检测路径是最大化其潜力的关键。

英文摘要

OBJECTIVES: Early detection and diagnosis of cancer is associated with greater treatment success and improved survival. Community pharmacies are often the first point of contact for patients with symptoms that could be due to cancer (e.g. persistent cough, rectal bleeding, dysphagia), and could contribute to earlier cancer detection.
METHODS: This systematic review assessed the evidence for community pharmacy-based interventions to support the early detection of cancer. Five databases (Medline, EMBASE, HMIC, CINAHL, and PSYCINFO) and other supplementary sources were searched for the time period January 2000-February 2025. Standard systematic review methodology following PRISMA guidelines was used. Independent duplicate screening, study selection, data extraction, and quality assessment were undertaken.
KEY FINDINGS: In total, 27 studies from 10 countries were included. Several cancer types were represented including colorectal (n = 13), lung (n = 4), skin (n = 4), breast (n = 1), prostate (n = 1), breast and cervical (n = 1), gastric (n = 1), colorectal and prostate (n = 1) and one study included multiple cancer types. The interventions included targeted screening (n = 2), population screening (n = 15), triage (n = 8) and health promotion (n = 2). From the 10 studies that reported cancer diagnosis rates, 3274 individuals had cancerous or precancerous lesions detected: colorectal (n = 2816); prostate (n = 14); and skin (n = 453), with a referral conversion rate ranging between 3.4% and 8.5%.
CONCLUSIONS: Harnessing the expertise of community pharmacy personnel is likely to support patients in an earlier and faster diagnosis of cancer. The integration of community pharmacy into early detection pathways is key to maximizing their potential.